Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment
Objective: Residual ovarian syndrome (ROS) occurs after a hysterectomy in which one or both ovaries have been preserved and cause chronic pelvic pain, an asymptomatic pelvic mass, or dyspareunia. We present a case with classic symptoms and imaging and pathology findings, and review the treatment of...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-10-01
|
Series: | Taiwanese Journal of Obstetrics & Gynecology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455918301943 |
id |
doaj-959a2afcd85d47199e35080548309732 |
---|---|
record_format |
Article |
spelling |
doaj-959a2afcd85d47199e350805483097322020-11-24T21:48:26ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592018-10-01575753754Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatmentShao-Chi Fu0Her-Young Su1Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, TaiwanCorresponding author. 5F, 325, Section 2, Cheng-Gong Road, Nei-Hu District, 114, Taipei, Taiwan.; Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, TaiwanObjective: Residual ovarian syndrome (ROS) occurs after a hysterectomy in which one or both ovaries have been preserved and cause chronic pelvic pain, an asymptomatic pelvic mass, or dyspareunia. We present a case with classic symptoms and imaging and pathology findings, and review the treatment of residual ovarian syndrome. Case report: A 35-year-old woman with a diagnosis of ROS. Conclusion: Based on previous literature, almost 50% of patients with ROS require surgery for their symptoms. Treatment of ROS with gonadotropin-releasing hormone analogs or high dose progestogens may be helpful. However, there are limited data supporting the efficacy of pharmacologic therapy. Patients receiving pharmacologic therapy should be counseled about the limited data supporting the efficacy of this approach, the lack of a histologic diagnosis, and the risk of ovarian cancer in residual tissue. Keywords: Residual ovarian syndrome, Pelvic pain, Gonadotropin-releasing hormone analogshttp://www.sciencedirect.com/science/article/pii/S1028455918301943 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shao-Chi Fu Her-Young Su |
spellingShingle |
Shao-Chi Fu Her-Young Su Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment Taiwanese Journal of Obstetrics & Gynecology |
author_facet |
Shao-Chi Fu Her-Young Su |
author_sort |
Shao-Chi Fu |
title |
Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment |
title_short |
Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment |
title_full |
Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment |
title_fullStr |
Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment |
title_full_unstemmed |
Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment |
title_sort |
residual ovarian syndrome: a case report with classic symptoms, imaging and pathology findings, and treatment |
publisher |
Elsevier |
series |
Taiwanese Journal of Obstetrics & Gynecology |
issn |
1028-4559 |
publishDate |
2018-10-01 |
description |
Objective: Residual ovarian syndrome (ROS) occurs after a hysterectomy in which one or both ovaries have been preserved and cause chronic pelvic pain, an asymptomatic pelvic mass, or dyspareunia. We present a case with classic symptoms and imaging and pathology findings, and review the treatment of residual ovarian syndrome. Case report: A 35-year-old woman with a diagnosis of ROS. Conclusion: Based on previous literature, almost 50% of patients with ROS require surgery for their symptoms. Treatment of ROS with gonadotropin-releasing hormone analogs or high dose progestogens may be helpful. However, there are limited data supporting the efficacy of pharmacologic therapy. Patients receiving pharmacologic therapy should be counseled about the limited data supporting the efficacy of this approach, the lack of a histologic diagnosis, and the risk of ovarian cancer in residual tissue. Keywords: Residual ovarian syndrome, Pelvic pain, Gonadotropin-releasing hormone analogs |
url |
http://www.sciencedirect.com/science/article/pii/S1028455918301943 |
work_keys_str_mv |
AT shaochifu residualovariansyndromeacasereportwithclassicsymptomsimagingandpathologyfindingsandtreatment AT heryoungsu residualovariansyndromeacasereportwithclassicsymptomsimagingandpathologyfindingsandtreatment |
_version_ |
1725892187295580160 |